Please login to the form below

Not currently logged in
Email:
Password:

Kite Pharma appoints cancer immunotherapy experts

Ronald Levy, Zelig Eshhar and Inder Verma will offer expert advice to US biotech

Ronald Levy, Kite Pharma Kite Pharma has added three experts in cancer immunotherapy to its scientific advisory board.

Dr Ronald Levy (pictured) is director of the lymphoma programme at Stanford University, Dr Zelig Eshhar is chairman of immunology research at the Tel Aviv Sourasky Medical Center, and Dr Inder Verma is chair of exemplary science and American Cancer Society professor of molecular biology at The Salk Institute.

Their expertise will help the US biotech develop medicines that activate the body's T cells to fight tumours.

Cancer immunotherapies are becoming a popular method of treatment for investigation in oncology, with big deals involving the likes of Bayer, Merck Serono, GSK and Roche.

"Kite is fortunate to attract these world-leading immunotherapy and cancer researchers to our advisory board," said Dr Aya Jakobovits, president and CEO of Kite.

Article by
Thomas Meek

12th August 2013

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Streaming Well

Streaming Well is a healthcare-focused, award-winning video production company which operates in the US and Europe. We create engaging visual...

Latest intelligence

Has the pandemic opened up a future of accelerated diagnosis and better care for rare disease patients?
The challenge with rare disease is in the name – it's rare, so awareness is limited and diagnosis hindered. Could a more virtual existence change this? A Medical Affairs viewpoint...
The other side of … blood cancer
To stay motivated for the fight, some patients need to feel like active players in the treatment journey, not passengers to every decision....
COVID clinical trial
COVID-19 – a catalyst for technology adoption in clinical trials
As the COVID-19 crisis disrupts clinical trials around the globe, it is also proving to be a catalyst that may transform its approach to trials for good...

Infographics